sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | There is no evidence that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | 0 |
Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | Our findings revealed that the optic nerve and optic radiation migth be vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | 1 |
Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may not be correlated with glaucoma severity and age. | -1 |
Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA may be correlated with glaucoma severity and age. | Our findings revealed that the optic nerve and optic radiation were vulnerable regions in patients with glaucoma and that FA is correlated with glaucoma severity and age. | 1 |
Furthermore, this study suggests that magnetic resonance imaging in patients with glaucoma may help to provide objective evidence to aid in the diagnosis and management of glaucoma. | Furthermore, this study suggests that magnetic resonance imaging in patients with glaucoma may not help to provide objective evidence to aid in the diagnosis and management of glaucoma. | -1 |
Furthermore, this study suggests that magnetic resonance imaging in patients with glaucoma may help to provide objective evidence to aid in the diagnosis and management of glaucoma. | Furthermore, there is no evidence that magnetic resonance imaging in patients with glaucoma may help to provide objective evidence to aid in the diagnosis and management of glaucoma. | 0 |
Furthermore, this study suggests that magnetic resonance imaging in patients with glaucoma may help to provide objective evidence to aid in the diagnosis and management of glaucoma. | Furthermore, this study suggests that magnetic resonance imaging in patients with glaucoma helps to provide objective evidence to aid in the diagnosis and management of glaucoma. | 1 |
This study shows an association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | This study shows no association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | -1 |
This study shows an association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | There is no evidence of an association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | 0 |
This study shows an association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | This study shows a possible association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. | 1 |
We found that POAG is associated with elevated plasma tHcy levels, but not serum folic acid, vitamin B(12), vitamin B(6) levels, or MTHFR C677T genotype. | We found that POAG is associated with decreased plasma tHcy levels, but not serum folic acid, vitamin B(12), vitamin B(6) levels, or MTHFR C677T genotype. | -1 |
We found that POAG is associated with elevated plasma tHcy levels, but not serum folic acid, vitamin B(12), vitamin B(6) levels, or MTHFR C677T genotype. | We found that POAG may be associated with elevated plasma tHcy levels, but not serum folic acid, vitamin B(12), vitamin B(6) levels, or MTHFR C677T genotype. | 1 |
We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a large cost difference. | We found an important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a large cost difference. | -1 |
We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a large cost difference. | We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, and there was no large cost difference. | -1 |
We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a large cost difference. | We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a small cost difference. | -1 |
Two small trials have suggested possible benefit of Gingko biloba on vision and further trials are warranted. | Two small trials have suggested no benefit of Gingko biloba on vision and further trials are warranted. | -1 |
Two small trials have suggested possible benefit of Gingko biloba on vision and further trials are warranted. | Two small trials have suggested possible detrimental effect of Gingko biloba on vision and further trials are warranted. | -1 |
Two small trials have suggested possible benefit of Gingko biloba on vision and further trials are warranted. | Two small trials have suggested benefit of Gingko biloba on vision and further trials are warranted. | 1 |
Cataract surgery increases visual acuity without an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | Cataract surgery increases visual acuity with an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | -1 |
Cataract surgery increases visual acuity without an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | Cataract surgery increases visual acuity without an decreased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | -1 |
Cataract surgery increases visual acuity without an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | Cataract surgery may increase visual acuity without an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged. | 1 |
Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were not better tolerated than those without releasable sutures. | -1 |
Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were tolerated worse than those without releasable sutures. | -1 |
Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | Although the two surgical procedures resulted in equivalent efficacy in IOP control, there is no evidence that the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | 0 |
Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures might be better tolerated than those without releasable sutures. | 1 |
Although the two surgical procedures resulted in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | Although there is no evidence that the two surgical procedures result in equivalent efficacy in IOP control, the trabeculectomies performed with releasable sutures were better tolerated than those without releasable sutures. | 0 |
Ranibizumab for diabetic macular edema is considered safe when the patients are carefully selected based on systemic vascular conditions and it is used on pro re nata basis. | There is no evidence that ranibizumab for diabetic macular edema is safe when the patients are carefully selected based on systemic vascular conditions and it is used on pro re nata basis. | 0 |
Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might be a protective factor against the development of glaucoma in Caucasian population. | Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might not be a protective factor against the development of glaucoma in Caucasian population. | -1 |
Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might be a protective factor against the development of glaucoma in Caucasian population. | Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might be a risk factor for the development of glaucoma in Caucasian population. | -1 |
Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might be a protective factor against the development of glaucoma in Caucasian population. | There is no evidence that MMP-9 rs17576 G > A polymorphism is a protective factor against the development of glaucoma in Caucasian population. | 0 |
Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism might be a protective factor against the development of glaucoma in Caucasian population. | Our meta-analysis demonstrates that MMP-9 rs17576 G > A polymorphism is a protective factor against the development of glaucoma in Caucasian population. | 1 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is not as effective as in-person examination but potentially increases patient participation in screening. | -1 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | There is no evidence that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | 0 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration may be as effective as in-person examination and potentially increases patient participation in screening. | 1 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination but does not potentially increase patient participation in screening. | -1 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination but potentially decreases patient participation in screening. | -1 |
The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening. | The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and increases patient participation in screening. | 1 |
However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | However, use of the DEX implant does not have higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | -1 |
However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | However, use of the DEX implant has lower risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | -1 |
However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | However, there is no evidence that use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | 0 |
However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | However, use of the DEX implant may have higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. | 1 |
Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. | Compared with anti-VEGF, DEX implant did not improve anatomical outcomes significantly. | -1 |
Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. | Compared with anti-VEGF, DEX implant worsened anatomical outcomes significantly. | -1 |
Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. | There is no evidence that compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. | 0 |
However, this did not translate to improved visual acuity, which may be due to the progression of cataract. | However, this translated to improved visual acuity, which may be due to the progression of cataract. | -1 |
However, this did not translate to improved visual acuity, which may be due to the progression of cataract. | However, this did not translate to worsened visual acuity, which may be due to the progression of cataract. | -1 |
Therefore, L107V and R390H might be the most important pathogenic mutations in Chinese PCG patients. | Therefore, L107V and R390H might not be the most important pathogenic mutations in Chinese PCG patients. | -1 |
Therefore, L107V and R390H might be the most important pathogenic mutations in Chinese PCG patients. | Therefore, L107V and R390H might be the least important pathogenic mutations in Chinese PCG patients. | -1 |
Therefore, L107V and R390H might be the most important pathogenic mutations in Chinese PCG patients. | Therefore, L107V and R390H are the most important pathogenic mutations in Chinese PCG patients. | 1 |
Intravitreal ranibizumab for the treatment of diabetic macular edema did not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | Intravitreal ranibizumab for the treatment of diabetic macular edema increased the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | -1 |
Intravitreal ranibizumab for the treatment of diabetic macular edema did not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | Intravitreal ranibizumab for the treatment of diabetic macular edema did not decrease the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | -1 |
Intravitreal ranibizumab for the treatment of diabetic macular edema did not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | There is no evidence that intravitreal ranibizumab for the treatment of diabetic macular edema did not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | 0 |
Intravitreal ranibizumab for the treatment of diabetic macular edema did not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | Intravitreal ranibizumab for the treatment of diabetic macular edema might not increase the risk for TEEs as shown by this meta-analysis of 4 randomized, controlled clinical trials. | 1 |
There is sufficient evidence that OH therapy reduces the risk of conversion to glaucoma. | There is sufficient evidence that OH therapy does not reduce the risk of conversion to glaucoma. | -1 |
There is sufficient evidence that OH therapy reduces the risk of conversion to glaucoma. | There is sufficient evidence that OH therapy increases the risk of conversion to glaucoma. | -1 |
There is sufficient evidence that OH therapy reduces the risk of conversion to glaucoma. | There is no evidence that OH therapy reduces the risk of conversion to glaucoma. | 0 |
There is sufficient evidence that OH therapy reduces the risk of conversion to glaucoma. | There is evidence that OH therapy may reduce the risk of conversion to glaucoma. | 1 |
Our meta-analysis results suggest that current smokers are at significantly increased risk of developing POAG. | Our meta-analysis results suggest that current smokers are not at significantly increased risk of developing POAG. | -1 |
Our meta-analysis results suggest that current smokers are at significantly increased risk of developing POAG. | Our meta-analysis results suggest that current smokers are at significantly decreased risk of developing POAG. | -1 |
Our meta-analysis results suggest that current smokers are at significantly increased risk of developing POAG. | There is no evidence that current smokers are at significantly increased risk of developing POAG. | 0 |
Our meta-analysis results suggest that current smokers are at significantly increased risk of developing POAG. | Our meta-analysis results suggest that current smokers may be at significantly increased risk of developing POAG. | 1 |
In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was identified, but no relationship with mortality was identified. | In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was not identified, and no relationship with mortality was identified. | -1 |
In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was identified, but no relationship with mortality was identified. | In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to less systemic vascular adverse events was identified, and no relationship with mortality was identified. | -1 |
In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was identified, but no relationship with mortality was identified. | In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was identified, and relationship with mortality was identified. | -1 |
Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02–1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13–1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98–1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96–1.31). | Late AMD might be associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02–1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13–1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98–1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96–1.31). | 1 |
Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02–1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13–1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98–1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96–1.31). | Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02–1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13–1.98), but early AMD might not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98–1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96–1.31). | 1 |
Glaucoma patients with visual field loss showed significantly poorer QoL relative to that of patients without glaucoma. | Glaucoma patients with visual field loss did not show significantly poorer QoL relative to that of patients without glaucoma. | -1 |
Glaucoma patients with visual field loss showed significantly poorer QoL relative to that of patients without glaucoma. | Glaucoma patients with visual field loss showed significantly better QoL relative to that of patients without glaucoma. | -1 |
Glaucoma patients with visual field loss showed significantly poorer QoL relative to that of patients without glaucoma. | There is no evidence that glaucoma patients with visual field loss showed significantly poorer QoL relative to that of patients without glaucoma. | 0 |
Patients' QoL decreased as their glaucoma severity increased. | Patients' QoL did not decrease as their glaucoma severity increased. | -1 |
Patients' QoL decreased as their glaucoma severity increased. | Patients' QoL increased as their glaucoma severity increased. | -1 |
Patients' QoL decreased as their glaucoma severity increased. | There is no evidence that patients' QoL decreased as their glaucoma severity increased. | 0 |
Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs is not better than medical treatment in reducing intraocular pressure. | Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs is better than medical treatment in reducing intraocular pressure. | -1 |
Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs is not better than medical treatment in reducing intraocular pressure. | Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs is not worse than medical treatment in reducing intraocular pressure. | -1 |
Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs is not better than medical treatment in reducing intraocular pressure. | Evidence from one small trial suggests that needling of encapsulated trabeculectomy blebs may not be better than medical treatment in reducing intraocular pressure. | 1 |
The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is not capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | -1 |
The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is incapable of maintaining visual acuity on a long-term basis of at least 4-5 years. | -1 |
The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | There is no evidence that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | 0 |
The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | The results of this meta-analysis indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years. | 1 |
Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably effective in preventing visual loss though there is doubt about the size of the effect. | Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably not effective in preventing visual loss though there is doubt about the size of the effect. | -1 |
Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably effective in preventing visual loss though there is doubt about the size of the effect. | Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably ineffective in preventing visual loss though there is doubt about the size of the effect. | -1 |
At present there is not enough evidence to recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration. | At present there is enough evidence to recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration. | -1 |
At present there is not enough evidence to recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration. | At present we recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration. | 0 |
Some food supplements and moderate aerobic exercise may also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | Some food supplements and moderate aerobic exercise may not also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | -1 |
Some food supplements and moderate aerobic exercise may also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | Some food supplements and moderate aerobic exercise may also increase intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | -1 |
Some food supplements and moderate aerobic exercise may also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | There is no evidence that some food supplements and moderate aerobic exercise also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | 0 |
Some food supplements and moderate aerobic exercise may also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | Some food supplements and moderate aerobic exercise also reduce intraocular pressure up to 2.0 and 3.0 mmHg, respectively. | 1 |
Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might not be a risk factor for POAG. | Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might be a risk factor for POAG. | -1 |
Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might not be a risk factor for POAG. | Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might not be a protective factor for POAG. | -1 |
Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might not be a risk factor for POAG. | There is no evidence that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might be a risk factor for POAG. | 0 |
Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 might not be a risk factor for POAG. | Our study indicated that rs1533428, rs12994401, rs10202118 polymorphism on chromosome 2p16.3 are not be a risk factor for POAG. | 1 |
A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. | A lower pooled mean IOP and higher complete and qualified success rates were not observed in the MMC arm than in the 5-FU arm. | -1 |
A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. | A higher pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. | -1 |
A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. | There is no evidence that a lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. | 0 |
Epithelial corneal defects were the unique complication reported more frequently with 5-FU compared to MMC treatment. | Epithelial corneal defects were the unique complication reported less frequently with 5-FU compared to MMC treatment. | -1 |
The trial did show a superiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | The trial did not show a superiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | -1 |
The trial did show a superiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | The trial did show a inferiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | -1 |
The trial did show a superiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | There is no evidence of superiority of conjunctival advancement, which was regarded as standard treatment, to amniotic membrane transplantation. | 0 |
Physical activity is associated with lower odds of early and late AMD in white populations. | Physical activity is not associated with lower odds of early and late AMD in white populations. | -1 |
Physical activity is associated with lower odds of early and late AMD in white populations. | Physical activity is associated with higher odds of early and late AMD in white populations. | -1 |